Also known as Tasigna
Nilotinib (AMN107, trade name Tasigna), in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved for the treatment of chronic myelogenous leukemia.
Source: WikipediaEstimated Total Cost: $6625.66 for an average of 28 days supply
Patients are most commonly prescribed nilotinib to treat leukemia, rabies, pick disease, and blastomycosis.
Critical Interactions
Significant Interactions